

Ambee Pharmaceuticals Limited

Statement of Financial Position

As at 30th September 2015

(Unaudited)

Taka '000

	<u>30th Sept. 2015</u>	<u>31st Dec. 2014</u>
ASSETS		
Non-Current Assets:	47,769	49,725
Property, Plant & Equipment-Carrying Value	47,769	49,725
Current Assets:	343,379	367,342
Inventories	165,186	183,503
Accounts Receivable	77,532	81,641
Advances, Deposits and Pre-payments	74,820	75,622
Short Term Investments	10,567	10,900
Cash and Cash Equivalents	15,274	15,676
Total Assets	391,148	417,067
EQUITY AND LIABILITIES		
Capital and Reserve:	58,816	58,102
Share Capital	24,000	24,000
Tax Holiday Reserve	5,134	5,134
Retained Earnings	29,682	28,968
Non-Current Liabilities:		
Deferred-tax Liability	8,082	8,320
Current Liabilities and Provisions:	324,250	350,645
Bank Loans (Secured)	211,711	224,569
Creditors and Other Payables	112,539	126,076
Total Equity and Liabilities	391,148	417,067
Net Asset Value per share (NAV)	24.51	24.21



(Aziz Mohammad Bhai)
Chairman




(Naureen Aziz Mohammad Bhai)
Managing Director



(Nurjehan Hudda)
Director



(A.K.M. Khairul Aziz)
Chief Financial Officer



(Anit Malaker)
Company Secretary

Ambee Pharmaceuticals Limited
Statement of Comprehensive Income
For the 3rd Quarter ended 30th September 2015
(Unaudited)

	<i>Taka '000</i>			
	<i>9 Month ended <u>Jan-Sept. 15</u></i>	<i>9 Month ended <u>Jan-Sept. 14</u></i>	<i>3rd Quarter 15 <u>July-Sept. 15</u></i>	<i>3rd Quarter 14 <u>July-Sept. 14</u></i>
Revenue (Turnover) from Net Sales	278,921	275,326	86,574	105,344
Cost of Goods Sold	(123,841)	(117,564)	(38,439)	(42,262)
Gross Profit	155,080	157,762	48,135	63,082
Operating Expenses :	(131,511)	(134,111)	(39,665)	(52,945)
Administrative Expenses	(13,249)	(12,995)	(3,401)	(4,326)
Marketing and Selling Expenses	(118,263)	(121,116)	(36,265)	(48,619)
Profit for Operation	23,569	23,651	8,470	10,137
Non Operating Income	806	-	208	-
Financial Expenses	(13,978)	(12,044)	(4,255)	(3,779)
Profit Before Contribution to WPPF	10,397	11,607	4,423	6,358
Contribution to WPPF	(520)	-	(221)	-
Net Profit before income-tax	9,877	11,607	4,202	6,358
Provision for income -tax	(2,443)	(3,192)	(896)	(1,748)
Current Tax	(2,681)	(3,192)	(998)	(1,748)
Deferred Tax Income/ (Expenses)	238		102	
Net Profit after income-tax	7,434	8,415	3,306	4,610
Number of Shares	2,400	2,400	2,400	2,400
Earnings Per Share (EPS)	3.10	3.51	1.38	1.92




(Aziz Mohammad Bhai)
Chairman




(Naureen Aziz Mohammad Bhai)
Managing Director



(Nurjehan Hudda)
Director



(A.K.M. Khairul Aziz)
Chief Financial Officer



(Anit Malaker)
Company Secretary

Ambee Pharmaceuticals Limited
Statement of Cash Flows (Un-audited)
For the period from 01 January 2015 to 30th September 2015
(Unaudited)

	<i>Taka '000</i>	
	<i>3rd Quarter 15</i>	<i>3rd Quarter 14</i>
	<i>Jan-Sept 2015</i>	<i>Jan-Sept 2014</i>
Cash Flows from Operating Activities :		
Collection from turnover	283,836	279,602
Payments for cost and expenses	(259,460)	(257,025)
Finance Expenses	(13,978)	(12,044)
Income-tax paid/deducted at source	(2,609)	(3,022)
Cash Generated from Operating Activities :	7,789	7,511
Cash Flows from Investing Activities :		
Acquisition of Fixed Assets	(442)	(1,045)
Cash Generated From Investment Activities	(442)	(1,045)
Cash Flows from Financing Activities :		
Other Finance	(1,680)	(8,770)
Dividend paid	(6,402)	(3,000)
Cash Generated From Financial Activities	(8,082)	(11,770)
Increase/(Decrease) in cash and cash equivalents	(735)	(5,304)
Opening cash and cash equivalents	26,576	23,425
Closing Cash and Bank balances	25,841	18,121
Net Operating cash flow per share	3.25	3.13
Components of Cash and Cash Equivalents		
Cash and Cash Equivalents	15,274	8,121
Short Term Investment	10,567	10,000
Total Cash and Cash Equivalents	25,841	18,121




(Aziz Mohammad Bhai)
Chairman




(Naureen Aziz Mohammad Bhai)
Managing Director



(Nurjehan Hudda)
Director



(A.K.M. Khairul Aziz)
Chief Financial Officer



(Anit Malaker)
Company Secretary

Ambee Pharmaceuticals Limited
Statement of Changes in Equity
For the 3rd quarter ended September 30, 2015
(Unaudited)

Taka '000

	Share Capital	Tax Holiday Reserve	Retained Earning	Total
At 1st January 2015	24,000	5,134	28,968	58,102
Dividend Paid for the year 2014			(6,720)	
Net Profit after income-tax January to Septmber 2015	-	-	7,434	7,434
At 30th September 2015	24,000	5,134	29,682	58,816
At 31st December 2014	24,000	5,134	28,968	58,102

Statement of Changes in Equity
For the 3rd Quarter ended September 30, 2014
(Unaudited)

Taka '000

	Share Capital	Tax Holiday Reserve	Retained Earning	Total
At 1st January 2014	20,000	5,134	28,445	53,579
Issued Bonus Share	4,000			4,000
Dividend Paid for the year 2013			(3,000)	(3,000)
Net Profit after income-tax January to September 2014	-	-	8,415	8,415
At 30th September 2014	24,000	5,134	33,860	62,994
At 31st December 2013	20,000	5,134	28,445	53,579

Note: Certain comparative figures have been reclassified from statements previously presented to conform to the presentation adopted for the 3rd quarter ended 30 September 2015.




(Aziz Mohammad Bhai)
Chairman




(Naureen Aziz Mohammad Bhai)
Managing Director



(Nurjehan Hudda)
Director



(A.K.M. Khairul Aziz)
Chief Financial Officer



(Anit Malaker)
Company Secretary

Dhaka
29th October, 2015